{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:55:42Z","timestamp":1792626942767,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The Ras family of small Guanosine Triphosphate (GTP)-binding proteins (G proteins) represents one of the main components of intracellular signal transduction required for normal cardiac growth, but is also critically involved in the development of cardiac hypertrophy and heart failure. The present review provides an update on the role of the H-, K- and N-Ras genes and their related pathways in cardiac diseases. We focus on cardiac hypertrophy and heart failure, where Ras has been studied the most. We also review other cardiac diseases, like genetic disorders related to Ras. The scope of the review extends from fundamental concepts to therapeutic applications. Although the three Ras genes have a nearly identical primary structure, there are important functional differences between them: H-Ras mainly regulates cardiomyocyte size, whereas K-Ras regulates cardiomyocyte proliferation. N-Ras is the least studied in cardiac cells and is less associated to cardiac defects. Clinically, oncogenic H-Ras causes Costello syndrome and facio-cutaneous-skeletal syndromes with hypertrophic cardiomyopathy and arrhythmias. On the other hand, oncogenic K-Ras and alterations of other genes of the Ras-Mitogen-Activated Protein Kinase (MAPK) pathway, like Raf, cause Noonan syndrome and cardio-facio-cutaneous syndromes characterized by cardiac hypertrophy and septal defects. We further review the modulation by Ras of key signaling pathways in the cardiomyocyte, including: (i) the classical Ras-Raf-MAPK pathway, which leads to a more physiological form of cardiac hypertrophy; as well as other pathways associated with pathological cardiac hypertrophy, like (ii) The SAPK (stress activated protein kinase) pathways p38 and JNK; and (iii) The alternative pathway Raf-Calcineurin-Nuclear Factor of Activated T cells (NFAT). Genetic alterations of Ras isoforms or of genes in the Ras-MAPK pathway result in Ras-opathies, conditions frequently associated with cardiac hypertrophy or septal defects among other cardiac diseases. Several studies underline the potential role of H- and K-Ras as a hinge between physiological and pathological cardiac hypertrophy, and as potential therapeutic targets in cardiac hypertrophy and failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s40659-021-00342-6","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T06:02:58Z","timestamp":1627970578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies"],"prefix":"10.1186","volume":"54","author":[{"given":"Manuel","family":"Ramos-Kuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harika","family":"Meka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Salamanca-Buentello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Lipskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie R.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"342_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2119\/molmed.2011.00512","volume":"18","author":"V Sala","year":"2012","unstructured":"Sala V, Gallo S, Leo C, Gatti S, Gelb BD, Crepaldi T. Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol Med. 2012;18:938\u201347.","journal-title":"Mol Med"},{"issue":"4","key":"342_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.yjmcc.2008.01.011","volume":"44","author":"F Lezoualc'h","year":"2008","unstructured":"Lezoualc\u2019h F, Metrich M, Hmitou I, Duquesnes N, Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol. 2008;44(4):623\u201332.","journal-title":"J Mol Cell Cardiol"},{"issue":"Pt 5","key":"342_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1242\/jcs.01660","volume":"118","author":"K Wennerberg","year":"2005","unstructured":"Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005;118(Pt 5):843\u20136.","journal-title":"J Cell Sci"},{"issue":"10","key":"342_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457\u201367.","journal-title":"Cancer Res"},{"issue":"3","key":"342_CR5","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/S0021-9258(18)53988-0","volume":"268","author":"A Thorburn","year":"1993","unstructured":"Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR, et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem. 1993;268(3):2244\u20139.","journal-title":"J Biol Chem"},{"issue":"9","key":"342_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb0904-807","volume":"6","author":"KR Chien","year":"2004","unstructured":"Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol. 2004;6(9):807\u20138.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"342_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1172\/JCI46399","volume":"121","author":"BD Gelb","year":"2011","unstructured":"Gelb BD, Tartaglia M. RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. J Clin Invest. 2011;121(3):844\u20137.","journal-title":"J Clin Invest"},{"issue":"1","key":"342_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1067\/mnc.2000.103724","volume":"7","author":"KH Lee","year":"2000","unstructured":"Lee KH, Hajjar RJ, Matsui T, Choukroun G, Force TL, Rosenzweig A. Cardiac signal transduction. J Nucl Cardiol. 2000;7(1):63\u201371.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"342_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","volume":"90","author":"BA Rose","year":"2010","unstructured":"Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507\u201346.","journal-title":"Physiol Rev"},{"issue":"5","key":"342_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2174\/1389557515666151001141838","volume":"16","author":"A Erijman","year":"2016","unstructured":"Erijman A, Shifman JM. RAS\/effector interactions from structural and biophysical perspective. Mini Rev Med Chem. 2016;16(5):370\u20135.","journal-title":"Mini Rev Med Chem"},{"key":"342_CR11","doi-asserted-by":"publisher","first-page":"D452","DOI":"10.2741\/Petkova","volume":"5","author":"SB Petkova","year":"2000","unstructured":"Petkova SB, Ashton A, Bouzahzah B, Huang H, Pestell RG, Tanowitz HB. Cell cycle molecules and diseases of the cardiovascular system. Front Biosci. 2000;5:D452\u201360.","journal-title":"Front Biosci"},{"issue":"22","key":"342_CR12","doi-asserted-by":"publisher","first-page":"14057","DOI":"10.1074\/jbc.272.22.14057","volume":"272","author":"MT Ramirez","year":"1997","unstructured":"Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem. 1997;272(22):14057\u201361.","journal-title":"J Biol Chem"},{"issue":"8","key":"342_CR13","doi-asserted-by":"publisher","first-page":"e72430","DOI":"10.1371\/journal.pone.0072430","volume":"8","author":"B Lei","year":"2013","unstructured":"Lei B, Schwinn DA, Morris DP. Stimulation of alpha1a adrenergic receptors induces cellular proliferation or antiproliferative hypertrophy dependent solely on agonist concentration. PLoS One. 2013;8(8):e72430.","journal-title":"PLoS One."},{"issue":"5","key":"342_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.biocel.2008.09.032","volume":"41","author":"N Duquesnes","year":"2009","unstructured":"Duquesnes N, Vincent F, Morel E, Lezoualc\u2019h F, Crozatier B. The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch. Int J Biochem Cell Biol. 2009;41(5):1173\u201381.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"342_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrm2597","volume":"10","author":"DE Jaalouk","year":"2009","unstructured":"Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol. 2009;10(1):63\u201373.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"342_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.jpcb.5b11110","volume":"120","author":"M Chakrabarti","year":"2016","unstructured":"Chakrabarti M, Jang H, Nussinov R. Comparison of the conformations of KRAS isoforms, K-Ras4A and K-Ras4B, points to similarities and significant differences. J Phys Chem B. 2016;120(4):667\u201379.","journal-title":"J Phys Chem B"},{"issue":"10","key":"342_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/ng1008-1149","volume":"40","author":"A Berns","year":"2008","unstructured":"Berns A. Kras and Hras\u2013what is the difference? Nat Genet. 2008;40(10):1149\u201350.","journal-title":"Nat Genet"},{"issue":"7","key":"342_CR18","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1074\/jbc.M209807200","volume":"278","author":"D Matallanas","year":"2003","unstructured":"Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, et al. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem. 2003;278(7):4572\u201381.","journal-title":"J Biol Chem"},{"issue":"11","key":"342_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"342_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401\u201338.","journal-title":"Arch Toxicol"},{"issue":"5","key":"342_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/HYPERTENSIONAHA.106.079426","volume":"49","author":"GW Dorn 2nd","year":"2007","unstructured":"Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49(5):962\u201370.","journal-title":"Hypertension"},{"issue":"4","key":"342_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","volume":"34","author":"JR McMullen","year":"2007","unstructured":"McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol. 2007;34(4):255\u201362.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"21","key":"342_CR23","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1113\/jphysiol.2013.258731","volume":"591","author":"ER Chemaly","year":"2013","unstructured":"Chemaly ER, Kang S, Zhang S, McCollum L, Chen J, Benard L, et al. Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin. J Physiol. 2013;591(21):5337\u201355.","journal-title":"J Physiol"},{"issue":"1","key":"342_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.yjmcc.2011.03.001","volume":"51","author":"PS Dhandapany","year":"2011","unstructured":"Dhandapany PS, Fabris F, Tonk R, Illaste A, Karakikes I, Sorourian M, et al. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol. 2011;51(1):4\u201315.","journal-title":"J Mol Cell Cardiol"},{"issue":"11 Pt A","key":"342_CR25","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1016\/j.bbamcr.2015.08.006","volume":"1853","author":"M Ramos-Kuri","year":"2015","unstructured":"Ramos-Kuri M, Rapti K, Mehel H, Zhang S, Dhandapany PS, Liang L, et al. Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. Biochim Biophys Acta. 2015;1853(11 Pt A):2870\u201384.","journal-title":"Biochim Biophys Acta."},{"issue":"1","key":"342_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrm3495","volume":"14","author":"M Maillet","year":"2013","unstructured":"Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. 2013;14(1):38\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"342_CR27","doi-asserted-by":"publisher","first-page":"H424","DOI":"10.1152\/ajpheart.00110.2003","volume":"286","author":"M Zheng","year":"2004","unstructured":"Zheng M, Dilly K, Dos Santos CJ, Li M, Gu Y, Ursitti JA, et al. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol. 2004;286(1):H424\u201333.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"34","key":"342_CR28","doi-asserted-by":"publisher","first-page":"21730","DOI":"10.1074\/jbc.273.34.21730","volume":"273","author":"PD Ho","year":"1998","unstructured":"Ho PD, Zechner DK, He H, Dillmann WH, Glembotski CC, McDonough PM. The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes. J Biol Chem. 1998;273(34):21730\u20135.","journal-title":"J Biol Chem"},{"issue":"9","key":"342_CR29","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1073\/pnas.94.9.4710","volume":"94","author":"KR Gottshall","year":"1997","unstructured":"Gottshall KR, Hunter JJ, Tanaka N, Dalton N, Becker KD, Ross J Jr, et al. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc Natl Acad Sci U S A. 1997;94(9):4710\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"342_CR30","doi-asserted-by":"publisher","first-page":"23173","DOI":"10.1074\/jbc.270.39.23173","volume":"270","author":"JJ Hunter","year":"1995","unstructured":"Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270(39):23173\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"342_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.RES.83.6.594","volume":"83","author":"H Kai","year":"1998","unstructured":"Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998;83(6):594\u2013601.","journal-title":"Circ Res"},{"issue":"2","key":"342_CR32","first-page":"109","volume":"61","author":"BR Wei","year":"2011","unstructured":"Wei BR, Martin PL, Hoover SB, Spehalski E, Kumar M, Hoenerhoff MJ, et al. Capacity for resolution of Ras-MAPK-initiated early pathogenic myocardial hypertrophy modeled in mice. Comp Med. 2011;61(2):109\u201318.","journal-title":"Comp Med"},{"issue":"10","key":"342_CR33","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/sj.onc.1201284","volume":"15","author":"K Koera","year":"1997","unstructured":"Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T, et al. K-ras is essential for the development of the mouse embryo. Oncogene. 1997;15(10):1151\u20139.","journal-title":"Oncogene"},{"issue":"46","key":"342_CR34","doi-asserted-by":"publisher","first-page":"16395","DOI":"10.1073\/pnas.1418126111","volume":"111","author":"I Hernandez-Porras","year":"2014","unstructured":"Hernandez-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Canamero M, Camara JA, et al. K-RasV14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A. 2014;111(46):16395\u2013400.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"342_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003658","volume":"10","author":"T Matsuda","year":"2017","unstructured":"Matsuda T, Jeong JI, Ikeda S, Yamamoto T, Gao S, Babu GJ, et al. H-Ras isoform mediates protection against pressure overload-induced cardiac dysfunction in part through activation of AKT. Circ Heart Fail.\n2017 10(2):e003658. doi:  https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003658.","journal-title":"Circ Heart Fail."},{"issue":"4","key":"342_CR36","first-page":"245","volume":"32","author":"WJ van Houdt","year":"2010","unstructured":"van Houdt WJ, de Bruijn MT, Emmink BL, Raats D, Hoogwater FJ, Borel Rinkes IH, et al. Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition. Cell Oncol. 2010;32(4):245\u201357.","journal-title":"Cell Oncol"},{"issue":"1","key":"342_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng.497","volume":"42","author":"IC Cirstea","year":"2010","unstructured":"Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010;42(1):27\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"342_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/1947601911408081","volume":"2","author":"E Castellano","year":"2011","unstructured":"Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216\u201331.","journal-title":"Genes Cancer"},{"issue":"5","key":"342_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrm1105","volume":"4","author":"JF Hancock","year":"2003","unstructured":"Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003;4(5):373\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"342_CR40","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/MCB.21.5.1444-1452.2001","volume":"21","author":"LM Esteban","year":"2001","unstructured":"Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21(5):1444\u201352.","journal-title":"Mol Cell Biol"},{"issue":"21","key":"342_CR41","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1038\/sj.onc.1210956","volume":"27","author":"K Nakamura","year":"2008","unstructured":"Nakamura K, Ichise H, Nakao K, Hatta T, Otani H, Sakagami H, et al. Partial functional overlap of the three ras genes in mouse embryonic development. Oncogene. 2008;27(21):2961\u20138.","journal-title":"Oncogene"},{"issue":"5","key":"342_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/sj.embor.7400397","volume":"6","author":"N Potenza","year":"2005","unstructured":"Potenza N, Vecchione C, Notte A, De Rienzo A, Rosica A, Bauer L, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep. 2005;6(5):432\u20137.","journal-title":"EMBO Rep"},{"issue":"1","key":"342_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ajmg.c.31765","volume":"184","author":"L Linglart","year":"2020","unstructured":"Linglart L, Gelb BD. Congenital heart defects in Noonan syndrome: diagnosis, management, and treatment. Am J Med Genet C Semin Med Genet. 2020;184(1):73\u201380.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"342_CR44","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/j.1460-2075.1996.tb00413.x","volume":"15","author":"J Sadoshima","year":"1996","unstructured":"Sadoshima J, Izumo S. The heterotrimeric G q protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. EMBO J. 1996;15(4):775\u201387.","journal-title":"EMBO J"},{"issue":"4","key":"342_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCULATIONAHA.114.010686","volume":"131","author":"M Bisserier","year":"2015","unstructured":"Bisserier M, Berthouze-Duquesnes M, Breckler M, Tortosa F, Fazal L, de Regibus A, et al. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+\/calmodulin-dependent protein kinase II signaling. Circulation. 2015;131(4):390\u2013400 (discussion).","journal-title":"Circulation."},{"issue":"10","key":"342_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4161\/cc.3.10.1182","volume":"3","author":"MC Harrisingh","year":"2004","unstructured":"Harrisingh MC, Lloyd AC. Ras\/Raf\/ERK signalling and NF1. Cell Cycle. 2004;3(10):1255\u20138.","journal-title":"Cell Cycle"},{"issue":"22","key":"342_CR47","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1242\/dev.125.22.4359","volume":"125","author":"MM Lakkis","year":"1998","unstructured":"Lakkis MM, Epstein JA. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development. 1998;125(22):4359\u201367.","journal-title":"Development"},{"issue":"2","key":"342_CR48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcm.2003.11.002","volume":"14","author":"BG Petrich","year":"2004","unstructured":"Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med. 2004;14(2):50\u20135.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"342_CR49","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCRESAHA.109.201509","volume":"105","author":"J Xu","year":"2009","unstructured":"Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res. 2009;105(3):304\u201311.","journal-title":"Circ Res"},{"issue":"6","key":"342_CR50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00424-014-1515-1","volume":"466","author":"A Guellich","year":"2014","unstructured":"Guellich A, Mehel H, Fischmeister R. Cyclic AMP synthesis and hydrolysis in the normal and failing heart. Pflugers Arch. 2014;466(6):1163\u201375.","journal-title":"Pflugers Arch"},{"issue":"5","key":"342_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.yjmcc.2010.11.011","volume":"50","author":"JK Gwathmey","year":"2011","unstructured":"Gwathmey JK, Yerevanian AI, Hajjar RJ. Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol. 2011;50(5):803\u201312.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"342_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/jcdd5010009","volume":"5","author":"M Laudette","year":"2018","unstructured":"Laudette M, Zuo H, Lezoualc\u2019h F, Schmidt M. Epac function and cAMP scaffolds in the heart and lung. J Cardiovasc Dev Dis. 2018;5(1):9.","journal-title":"J Cardiovasc Dev Dis."},{"issue":"3","key":"342_CR53","doi-asserted-by":"publisher","first-page":"H1662","DOI":"10.1152\/ajpheart.00159.2007","volume":"293","author":"C Ulucan","year":"2007","unstructured":"Ulucan C, Wang X, Baljinnyam E, Bai Y, Okumura S, Sato M, et al. Developmental changes in gene expression of Epac and its upregulation in myocardial hypertrophy. Am J Physiol Heart Circ Physiol. 2007;293(3):H1662\u201372.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"342_CR54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1161\/CIRCRESAHA.107.164947","volume":"102","author":"M Metrich","year":"2008","unstructured":"Metrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, Morel E, et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res. 2008;102(8):959\u201365.","journal-title":"Circ Res"},{"issue":"1","key":"342_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1517\/14712590903321462","volume":"10","author":"L Lipskaia","year":"2010","unstructured":"Lipskaia L, Chemaly ER, Hadri L, Lompre AM, Hajjar RJ. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther. 2010;10(1):29\u201341.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"342_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/14796678.3.4.413","volume":"3","author":"L Lipskaia","year":"2007","unstructured":"Lipskaia L, Ly H, Kawase Y, Hajjar RJ, Lompre AM. Treatment of heart failure by calcium cycling gene therapy. Future Cardiol. 2007;3(4):413\u201323.","journal-title":"Future Cardiol"},{"issue":"9","key":"342_CR57","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/01.RES.87.9.731","volume":"87","author":"JD Molkentin","year":"2000","unstructured":"Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87(9):731\u20138.","journal-title":"Circ Res"},{"issue":"7","key":"342_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1_suppl","key":"342_CR59","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1177\/14703203010020012701","volume":"2","author":"D Lebeche","year":"2001","unstructured":"Lebeche D, Zhao Bin K, Hajjar R. Candesartan abrogates G protein-coupled receptors agonist-induced MAPK activation and cardiac myocyte hypertrophy. J Renin Angiotensin Aldosterone Syst. 2001;2(1_suppl):S154\u201361.","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"issue":"3","key":"342_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1254\/jphs.09336FP","volume":"113","author":"GX Zhang","year":"2010","unstructured":"Zhang GX, Kimura S, Murao K, Yu X, Obata K, Matsuyoshi H, et al. Effects of angiotensin type I receptor blockade on the cardiac Raf\/MEK\/ERK cascade activated via adrenergic receptors. J Pharmacol Sci. 2010;113(3):224\u201333.","journal-title":"J Pharmacol Sci"},{"issue":"14","key":"342_CR61","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1136\/heartjnl-2012-302970","volume":"99","author":"ER Chemaly","year":"2013","unstructured":"Chemaly ER, Hajjar RJ, Lipskaia L. Molecular targets of current and prospective heart failure therapies. Heart. 2013;99(14):992\u20131003.","journal-title":"Heart"},{"issue":"4\u20136","key":"342_CR62","first-page":"337","volume":"7","author":"T Force","year":"1999","unstructured":"Force T, Hajjar R, Del Monte F, Rosenzweig A, Choukroun G. Signaling pathways mediating the response to hypertrophic stress in the heart. Gene Expr. 1999;7(4\u20136):337\u201348.","journal-title":"Gene Expr"},{"issue":"6","key":"342_CR63","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","volume":"110","author":"IS Harris","year":"2004","unstructured":"Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 2004;110(6):718\u201323.","journal-title":"Circulation"},{"issue":"7","key":"342_CR64","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1172\/JCI200420317","volume":"114","author":"O Yamaguchi","year":"2004","unstructured":"Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004;114(7):937\u201343.","journal-title":"J Clin Invest"},{"issue":"4","key":"342_CR65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1172\/JCI6350","volume":"104","author":"G Choukroun","year":"1999","unstructured":"Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases\/c-Jun NH(2)-terminal kinases. J Clin Invest. 1999;104(4):391\u20138.","journal-title":"J Clin Invest"},{"issue":"2","key":"342_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1161\/hy0202.102699","volume":"39","author":"R Aikawa","year":"2002","unstructured":"Aikawa R, Nagai T, Kudoh S, Zou Y, Tanaka M, Tamura M, et al. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension. 2002;39(2):233\u20138.","journal-title":"Hypertension"},{"issue":"4","key":"342_CR67","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1161\/01.HYP.32.4.668","volume":"32","author":"S Murasawa","year":"1998","unstructured":"Murasawa S, Mori Y, Nozawa Y, Masaki H, Maruyama K, Tsutsumi Y, et al. Role of calcium-sensitive tyrosine kinase Pyk2\/CAKbeta\/RAFTK in angiotensin II induced Ras\/ERK signaling. Hypertension. 1998;32(4):668\u201375.","journal-title":"Hypertension"},{"issue":"2","key":"342_CR68","doi-asserted-by":"publisher","first-page":"H695","DOI":"10.1152\/ajpheart.00021.2002","volume":"283","author":"AL Bayer","year":"2002","unstructured":"Bayer AL, Heidkamp MC, Patel N, Porter MJ, Engman SJ, Samarel AM. PYK2 expression and phosphorylation increases in pressure overload-induced left ventricular hypertrophy. Am J Physiol Heart Circ Physiol. 2002;283(2):H695-706.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"342_CR69","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1074\/jbc.M004275200","volume":"276","author":"M Ichida","year":"2001","unstructured":"Ichida M, Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem. 2001;276(5):3524\u201330.","journal-title":"J Biol Chem"},{"issue":"18","key":"342_CR70","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/138161211796390976","volume":"17","author":"T Aoyagi","year":"2011","unstructured":"Aoyagi T, Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des. 2011;17(18):1818\u201324.","journal-title":"Curr Pharm Des"},{"issue":"35","key":"342_CR71","doi-asserted-by":"publisher","first-page":"32670","DOI":"10.1074\/jbc.M102776200","volume":"276","author":"L Wang","year":"2001","unstructured":"Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J Biol Chem. 2001;276(35):32670\u20137.","journal-title":"J Biol Chem."},{"issue":"9","key":"342_CR72","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1161\/01.RES.0000041029.97988.E9","volume":"91","author":"L Wang","year":"2002","unstructured":"Wang L, Proud CG. Ras\/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res. 2002;91(9):821\u20139.","journal-title":"Circ Res"},{"issue":"6","key":"342_CR73","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.yjmcc.2008.07.016","volume":"45","author":"Y Wang","year":"2008","unstructured":"Wang Y, Huang BP, Luciani DS, Wang X, Johnson JD, Proud CG. Rheb activates protein synthesis and growth in adult rat ventricular cardiomyocytes. J Mol Cell Cardiol. 2008;45(6):812\u201320.","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"342_CR74","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tibs.2003.09.003","volume":"28","author":"BD Manning","year":"2003","unstructured":"Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28(11):573\u20136.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"342_CR75","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/01.CIR.103.5.670","volume":"103","author":"S Haq","year":"2001","unstructured":"Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103(5):670\u20137.","journal-title":"Circulation"},{"issue":"5","key":"342_CR76","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1172\/JCI40096","volume":"120","author":"I Shimizu","year":"2010","unstructured":"Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010;120(5):1506\u201314.","journal-title":"J Clin Invest"},{"issue":"5","key":"342_CR77","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1128\/MCB.01109-14","volume":"35","author":"AR Wende","year":"2015","unstructured":"Wende AR, O\u2019Neill BT, Bugger H, Riehle C, Tuinei J, Buchanan J, et al. Enhanced cardiac Akt\/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol Cell Biol. 2015;35(5):831\u201346.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"342_CR78","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/ijms20071599","volume":"20","author":"A Fiordelisi","year":"2019","unstructured":"Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int J Mol Sci. 2019;20(7):1599.","journal-title":"Int J Mol Sci."},{"issue":"8","key":"342_CR79","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00246-016-1468-6","volume":"37","author":"WK Jhang","year":"2016","unstructured":"Jhang WK, Choi JH, Lee BH, Kim GH, Yoo HW. Cardiac manifestations and associations with gene mutations in patients diagnosed with RASopathies. Pediatr Cardiol. 2016;37(8):1539\u201347.","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"342_CR80","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/chd.12102","volume":"9","author":"JL Colquitt","year":"2014","unstructured":"Colquitt JL, Noonan JA. Cardiac findings in Noonan syndrome on long-term follow-up. Congenit Heart Dis. 2014;9(2):144\u201350.","journal-title":"Congenit Heart Dis"},{"issue":"3","key":"342_CR81","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ajmg.a.33857","volume":"155A","author":"AE Lin","year":"2011","unstructured":"Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras\/MAPK pathway syndrome. Am J Med Genet A. 2011;155A(3):486\u2013507.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"342_CR82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1399-0004.2007.00931.x","volume":"73","author":"AL Schulz","year":"2008","unstructured":"Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, et al. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet. 2008;73(1):62\u201370.","journal-title":"Clin Genet"},{"issue":"7","key":"342_CR83","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1136\/jmg.2007.049361","volume":"44","author":"O Sovik","year":"2007","unstructured":"Sovik O, Schubbert S, Houge G, Steine SJ, Norgard G, Engelsen B, et al. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet. 2007;44(7):e84.","journal-title":"J Med Genet."},{"issue":"4","key":"342_CR84","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cge.12072","volume":"84","author":"R Nguyen","year":"2013","unstructured":"Nguyen R, Mir TS, Kluwe L, Jett K, Kentsch M, Mueller G, et al. Cardiac characterization of 16 patients with large NF1 gene deletions. Clin Genet. 2013;84(4):344\u20139.","journal-title":"Clin Genet"},{"issue":"8A","key":"342_CR85","doi-asserted-by":"publisher","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N.","journal-title":"Am J Cardiol"},{"issue":"7","key":"342_CR86","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","volume":"96","author":"BM Psaty","year":"1997","unstructured":"Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455\u201361.","journal-title":"Circulation"},{"issue":"10","key":"342_CR87","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/jhh.2011.105","volume":"26","author":"YF Lau","year":"2012","unstructured":"Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens. 2012;26(10):563\u20139.","journal-title":"J Hum Hypertens"},{"issue":"8","key":"342_CR88","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1139\/cjpp-2014-0416","volume":"93","author":"WW Wang","year":"2015","unstructured":"Wang WW, Zhang FL, Chen JH, Chen XH, Fu FY, Tang MR, et al. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats. Can J Physiol Pharmacol. 2015;93(8):657\u201365.","journal-title":"Can J Physiol Pharmacol"},{"issue":"6","key":"342_CR89","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0735-1097(00)00611-2","volume":"35","author":"A Goette","year":"2000","unstructured":"Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35(6):1669\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"342_CR90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cbf.1353","volume":"25","author":"I Al-Rashdan","year":"2007","unstructured":"Al-Rashdan I, Canatan H, Al-Maghrebi M, Yousif MH, Khan SA, Benter IF. Cardioprotection from ischemia-reperfusion injury due to Ras-GTPase inhibition is attenuated by glibenclamide in the globally ischemic heart. Cell Biochem Funct. 2007;25(4):455\u201361.","journal-title":"Cell Biochem Funct"},{"issue":"5","key":"342_CR91","doi-asserted-by":"publisher","first-page":"H2406","DOI":"10.1152\/ajpheart.00862.2007","volume":"294","author":"GF Kocsis","year":"2008","unstructured":"Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol. 2008;294(5):H2406\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"342_CR92","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139\u2013596.","journal-title":"Circulation"},{"issue":"2","key":"342_CR93","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"CW Yancy","year":"2018","unstructured":"Yancy CW, Januzzi JL Jr, Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71(2):201\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"342_CR94","doi-asserted-by":"publisher","first-page":"42965","DOI":"10.1038\/srep42965","volume":"7","author":"X Xiong","year":"2017","unstructured":"Xiong X, Yang X, Duan L, Liu W, Zhang Y, Liu Y, et al. Traditional Chinese medicine suppresses left ventricular hypertrophy by targeting extracellular signal-regulated kinases signaling pathway in spontaneously hypertensive rats. Sci Rep. 2017;7:42965.","journal-title":"Sci Rep"},{"issue":"6","key":"342_CR95","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/MCB.00989-10","volume":"31","author":"KJ Cho","year":"2011","unstructured":"Cho KJ, Hill MM, Chigurupati S, Du G, Parton RG, Hancock JF. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol. 2011;31(6):1110\u201320.","journal-title":"Mol Cell Biol"},{"issue":"16","key":"342_CR96","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1161\/01.CIR.0000034047.70205.97","volume":"106","author":"C Indolfi","year":"2002","unstructured":"Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 2002;106(16):2118\u201324.","journal-title":"Circulation"},{"issue":"4","key":"342_CR97","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/acn3.288","volume":"3","author":"CE Bearden","year":"2016","unstructured":"Bearden CE, Hellemann GS, Rosser T, Montojo C, Jonas R, Enrique N, et al. A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. Ann Clin Transl Neurol. 2016;3(4):266\u201379.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"342_CR98","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00702-016-1609-3","volume":"123","author":"F Mainberger","year":"2016","unstructured":"Mainberger F, Langer S, Mall V, Jung NH. Impaired synaptic plasticity in RASopathies: a mini-review. J Neural Transm (Vienna). 2016;123(10):1133\u20138.","journal-title":"J Neural Transm (Vienna)"},{"issue":"24","key":"342_CR99","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1212\/WNL.0000000000003435","volume":"87","author":"JM Payne","year":"2016","unstructured":"Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, et al. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87(24):2575\u201384.","journal-title":"Neurology"},{"key":"342_CR100","doi-asserted-by":"publisher","first-page":"39186","DOI":"10.1038\/srep39186","volume":"6","author":"CZ Zhao","year":"2016","unstructured":"Zhao CZ, Zhao XM, Yang J, Mou Y, Chen B, Wu HD, et al. Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodeling. Sci Rep. 2016;6:39186.","journal-title":"Sci Rep"},{"issue":"4","key":"342_CR101","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1016\/j.ijcard.2013.04.038","volume":"168","author":"X Li","year":"2013","unstructured":"Li X, Han J, Li L, Wang KJ, Hu SJ. Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats. Int J Cardiol. 2013;168(4):3340\u20137.","journal-title":"Int J Cardiol"},{"issue":"16","key":"342_CR102","doi-asserted-by":"publisher","first-page":"11216","DOI":"10.1074\/jbc.M112.442384","volume":"288","author":"RS Nagalingam","year":"2013","unstructured":"Nagalingam RS, Sundaresan NR, Gupta MP, Geenen DL, Solaro RJ, Gupta M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem. 2013;288(16):11216\u201332.","journal-title":"J Biol Chem"},{"key":"342_CR103","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1038\/ncomms15090","volume":"8","author":"SM Shin","year":"2017","unstructured":"Shin SM, Choi DK, Jung K, Bae J, Kim JS, Park SW, et al. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Nat Commun. 2017;8:15090.","journal-title":"Nat Commun"},{"issue":"11","key":"342_CR104","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.bbapap.2014.05.009","volume":"1844","author":"J Zhang","year":"2014","unstructured":"Zhang J, Rabbitts TH. Intracellular antibody capture: a molecular biology approach to inhibitors of protein-protein interactions. Biochim Biophys Acta. 2014;1844(11):1970\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"342_CR105","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1113\/JP274064","volume":"595","author":"K Lorenz","year":"2017","unstructured":"Lorenz K, Rosner MR, Brand T, Schmitt JP. Raf kinase inhibitor protein: lessons of a better way for beta-adrenergic receptor activation in the heart. J Physiol. 2017;595(12):4073\u201387.","journal-title":"J Physiol"},{"issue":"6","key":"342_CR106","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/01.RES.84.6.735","volume":"84","author":"T Meguro","year":"1999","unstructured":"Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999;84(6):735\u201340.","journal-title":"Circ Res"},{"issue":"3","key":"342_CR107","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1172\/JCI44972","volume":"121","author":"TM Marin","year":"2011","unstructured":"Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121(3):1026\u201343.","journal-title":"J Clin Invest"},{"issue":"23","key":"342_CR108","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","volume":"23","author":"PM Lorusso","year":"2005","unstructured":"Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281\u201393.","journal-title":"J Clin Oncol"},{"issue":"3","key":"342_CR109","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","volume":"121","author":"X Wu","year":"2011","unstructured":"Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH, et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf 1(L613V) mutation. J Clin Invest. 2011;121(3):1009\u201325.","journal-title":"J Clin Invest"},{"key":"342_CR110","doi-asserted-by":"publisher","first-page":"633661","DOI":"10.3389\/fcell.2021.633661","volume":"9","author":"X You","year":"2021","unstructured":"You X, Ryu MJ, Cho E, Sang Y, Damnernsawad A, Zhou Y, et al. Embryonic expression of Nras(G 12 D) leads to embryonic lethality and cardiac defects. Front Cell Dev Biol. 2021;9:633661.","journal-title":"Front Cell Dev Biol."},{"issue":"14","key":"342_CR111","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.4155\/fmc.11.121","volume":"3","author":"AT Baines","year":"2011","unstructured":"Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3(14):1787\u2013808.","journal-title":"Future Med Chem"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-021-00342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-021-00342-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-021-00342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T07:02:50Z","timestamp":1627974170000},"score":1,"resource":{"primary":{"URL":"https:\/\/biolres.biomedcentral.com\/articles\/10.1186\/s40659-021-00342-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1186\/s40659-021-00342-6","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of patients for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}